Most Read

A total of 79 patients with COPD have enrolled at sites in the U.S. and in the UK in this three way crossover study. It is anticipated that

Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have options to worldwide rights on up to five targets emerging from Tango’s proprietary

Fostemsavir, in combination with optimised background treatment (OBT), maintained virologic suppression from Week 24 to Week 48 in this difficult-to-treat population. Results show 54% of patients in the

The Frederick campus houses a recently expanded east coast distribution center, new Cryo-Innovation Center and the National Cancer Institute Central Repository for Clinical Trials. The site will help

Terns president and CEO Weidong Zhong said: “Since we launched the company a short time ago, we have been working diligently to advance our key programs and continue

The companies will utilize Dicerna’s proprietary GalXC RNAi technology platform to progress new drug targets toward clinical development and commercialization. In addition, the partners will collaborate to move

The companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, currently in Phase 2), a Diacylglycerol

In addition, there is an ongoing earn-out payment based as a percentage of net sales over a 10-year period. Under the terms of the asset purchase, license and

Brolucizumab met its primary endpoint of non-inferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal outcomes at year one (48 weeks). Secondary